Lawrence Bloch, M.D., J.D.
Lawrence Bloch, M.D., J.D. serves as president of Infinity. He joined Infinity as chief financial officer and chief business officer in 2012 and has played a key role in developing and executing the company's corporate and financial strategies. Prior to joining Infinity in 2012, Dr. Bloch served as chief executive officer of NeurAxon, Inc., a company focused on developing next-generation pain therapeutics, from 2007 to 2011. Previously, he served as chief business officer and chief financial officer of NitroMed, Inc., raising $150 million in equity and $20 million in venture debt to support the commercial launch of BiDil®. From 1999 to 2004, he served as chief financial officer and vice president of business development, of Applied Molecular Evolution, Inc., leading the company’s $101 million initial public offering and $420 million merger with Eli Lilly and Company.
Dr. Bloch began his career as an emergency medicine resident physician at Massachusetts General Hospital and Brigham & Woman’s Hospital. He holds a J.D. from Harvard Law School, an M.D. from Harvard Medical School and an MBA from Harvard Business School.
Claudio Dansky Ullmann, M.D. M.D.
Senior Vice President, Clinical Development
Claudio Dansky Ullmann, M.D., is senior vice president, clinical development, at Infinity. Dr. Dansky Ullmann has nearly 30 years of experience in drug development. Prior to joining Infinity, he served as a senior medical director, global clinical lead, at Takeda Pharmaceutical Company Limited from 2012 to 2015. From 2005 to 2012, Dr. Ullmann worked at the Cancer Therapy Evaluation Program of the National Cancer Institute as a senior investigator where he participated in numerous early-phase and late-phase clinical trials, including studies evaluating treatments for lung and head and neck cancers, melanoma and other solid tumors. During his career, Dr. Dansky Ullmann also held research roles at the National Institute of Health and at Biomira Inc., and he held postdoctoral fellowship positions in tumor immunology and drug resistance at the National Cancer Institute. Dr. Dansky Ullmann is a native of Argentina and earned his M.D. at the School of Medicine, Universidad de Buenos Aires. He completed his medical oncology training at Guemes Private Hospital, Buenos Aires.
Jeffery Kutok, M.D., Ph.D.
Chief Scientific Officer
Chair and Chief Executive Officer
Adelene Perkins serves as Infinity’s chief executive officer and Infinity’s chair, a position she has held since 2012. She was named chief executive officer and elected to the Board of Directors in 2009. Prior to becoming Infinity’s chief executive officer, Ms. Perkins served as Infinity’s President, a position she held since 2008. Ms. Perkins joined Infinity in June 2002 as executive vice president and chief business officer.
Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Pfizer, where she was vice president of emerging businesses and the cofounder and general manager of the DiscoverEase™ business unit. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry.
Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is on the Boards of BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, Bruker Corporation; and is the Vice Chairman of the Board of Project Hope, a multi-service agency committed to breaking the cycle of homelessness and poverty. She is a past member of the Boards of Padlock Therapeutics and the Massachusetts Life Science Center.
Vice President, General Counsel and Secretary